New androgen prostate cancer pathway found

Nov 08, 2006

U.S. scientists have discovered a specific biochemical pathway involved in the development of prostate cancer.

The pathway is used by the sex hormone androgen, which increases levels of harmful chemicals called reactive oxygen species in the prostate gland that play a role in the development of prostate cancer.

The scientists at the Carbone Comprehensive Cancer Center in Madison, Wis., found a drug that blocks the pathway significantly prolonged survival and inhibited tumor development in mice that were genetically engineered to spontaneously develop prostate cancer and die of the disease.

The hope is that the drug can eventually be used to treat men at high risk of developing prostate cancer and to prevent recurrences in men already treated for primary tumors.

The research was presented Wednesday by the study's principal investigator, Dr. Hirak Basu, during an international cancer conference in Prague, Czech Republic.

Copyright 2006 by United Press International

Explore further: Cancer: Tumors absorb sugar for mobility

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Why we should vaccinate boys against HPV as well as girls

1 hour ago

Gillian Prue, from the School of Nursing and Midwifery at Queen's University of Belfast, says that the human papillomavirus (HPV) infection is common in men and can lead to genital warts and the development of some head and ...

Generation of tanners see spike in deadly melanoma

14 hours ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

14 hours ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

User comments : 0